The following video is from Wednesday's MarketFoolery podcast in which host Chris Hill and analysts Charly Travers and Jason Moser discuss the top business and investing stories.
In this segment, Biogen had partnered with Elan on a drug to treat multiple sclerosis. This morning, Biogen bought Elan's stake in the drug for $3.25 billion plus future royalties. While shares of Elan fell on the news, shares of Biogen were up. Our analysts discuss what the deal means for investors.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The relevant video segment can be found between 10:11 and 13:33.
The article 1 Blockbuster Biotech Deal originally appeared on Fool.com.Charly Travers, Chris Hill, Jason Moser, and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.